Erratum: The IGF-I regulatory system and its impact on skeletal and energy homeostasis (Journal of Cellular Biochemistry (2010) 111 (14-19) DOI: 10.1002/jcb.22678);The IGF-I regulatory system and its impact on skeletal and energy homeostasis

Journal of Cellular Biochemistry

Volumn 111, Issue 1, 2010, Pages 14-19

  Kawai, Masanobu ^a   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

Bone; Fat; IGF binding protein; IGF I

Indexed keywords

SOMATOMEDIN C;

ADIPOGENESIS; ADIPOSE TISSUE; BONE DENSITY; CELL DIFFERENTIATION; ENERGY; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77956988551     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23442     Document Type: Erratum

References (49)

1. Ahmed RL, Thomas W, Schmitz KH. 2007. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 16:593-597. (Pubitemid 46548665)
2. Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ III, Khosla S. 2004. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 19:1075-1083.
3. Boney CM, Smith RM, Gruppuso PA. 1998. Modulation of insulin-like growth factor I mitogenic signaling in 3T3-L1 preadipocyte differentiation. Endocrinology 139:1638-1644.
4. Boney CM, Gruppuso PA, Faris RA, Frackelton AR, Jr. 2000. The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes. Mol Endocrinol 14:805-813.
5. Chan SS, Schedlich LJ, Twigg SM, Baxter RC. 2009. Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab 296:E654-E663.
6. Christoffersen CT, Tornqvist H, Vlahos CJ, Bucchini D, Jami J, De Meyts P, Joshi RL. 1998. Insulin and insulin-like growth factor-I receptor mediated differentiation of 3T3-F442A cells into adipocytes: Effect of PI 3-kinase inhibition. Biochem Biophys Res Commun 246:426-430.
7. Conover CA, Johnstone EW, Turner RT, Evans GL, John Ballard FJ, Doran PM, Khosla S. 2002. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res 12:178-183.
8. DeMambro VE, Kawai M, Clemens TL, Fulzele K, Maynard JA, Marin de Evsikova C, Johnson KR, Canalis E, Beamer WG, Rosen CJ, Donahue LR. 2010. A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis. J Endocrinol 204: 241-253.
9. Devlin RD, Du Z, Buccilli V, Jorgetti V, Canalis E. 2002. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143:3955-3962. (Pubitemid 35244375)
10. Elis S, Courtland HW, Wu Y, Rosen CJ, Sun H, Jepsen KJ, Majeska RJ, Yakar S. 2010. Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties, even in the absence of tissue IGF-1. J Bone Miner Res [Epub ahead of Print].
11. Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854.
12. Garnero P, Sornay-Rendu E, Delmas PD. 2000. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355:898-899.
13. He J, Rosen CJ, Adams DJ, Kream BE. 2006. Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. Bone 38:826-835. (Pubitemid 44498595)
14. Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E. 2001. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142:1889-1898.
15. Holzenberger M, Hamard G, Zaoui R, Leneuve P, Ducos B, Beccavin C, Perin L, Le Bouc Y. 2001. Experimental IGF-I receptor deficiency generates a sexually dimorphic pattern of organ-specific growth deficits in mice, affecting fat tissue in particular. Endocrinology 142:4469-4478.
16. Hu D, Pawlikowska L, Kanaya A, Hsueh WC, Colbert L, Newman AB, Satterfield S, Rosen C, Cummings SR, Harris TB, Ziv E. 2009. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: The Health, Aging, and Body Composition Study. J Am Geriatr Soc 57:1213-1218.
17. Hwa V, Oh Y, Rosenfeld RG. 1999. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787. (Pubitemid 30648894)
18. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
19. Kawai M, Rosen CJ. 2009. Insulin-like growth factor-I and bone: Lessons from mice and men. Pediatr Nephrol 24:1277-1285.
20. Khosla S, Hassoun AA, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL, Conover CA. 1998. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 101:2165-2173. (Pubitemid 28244100)
21. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP. 1998. Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study. J Clin Endocrinol Metab 83:4257-4262. (Pubitemid 29100118)
22. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.
23. Marques BG, Hausman DB, Latimer AM, Kras KM, Grossman BM, Martin RJ. 2000. Insulin-like growth factor I mediates high-fat diet-induced adipogenesis in Osborne-Mendel rats. Am J Physiol Regul Integr Comp Physiol 278:R654-R662.
24. Miki H, Yamauchi T, Suzuki R, Komeda K, Tsuchida A, Kubota N, Terauchi Y, Kamon J, Kaburagi Y, Matsui J, Akanuma Y, Nagai R, Kimura S, Tobe K, Kadowaki T. 2001. Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol 21:2521-2532.
25. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, Cohen P. 2009. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 23:169-175.
26. Nakaoka D, Sugimoto T, Kaji H, Kanzawa M, Yano S, Yamauchi M, Sugishita T, Chihara K. 2001. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteoporos Int 12:548-554. (Pubitemid 32777430)
27. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352-1365.
28. Rajkumar K, Modric T, Murphy LJ. 1999. Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J Endocrinol 162: 457-465. (Pubitemid 29447440)
29. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. 2008. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 18:166-173.
30. Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:885-896.
31. Rosen ED, Spiegelman BM. 2000. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16:145-171.
32. Rosen CJ, Donahue LR, Hunter SJ. 1994. Insulin-like growth factors and bone: The osteoporosis connection. Proc Soc Exp Biol Med 206:83-102. (Pubitemid 24188322)
33. Russo VC, Edmondson SR, Mercuri FA, Buchanan CR, Werther GA. 1994. Identification, localization, and regulation of insulin-like growth factor binding proteins and their messenger ribonucleic acids in the newborn rat olfactory bulb. Endocrinology 135:1437-1446.
34. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. 2002. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet 359:1740-1745.
35. Siddals KW, Westwood M, Gibson JM, White A. 2002. IGF-binding protein-1 inhibits IGF effects on adipocyte function: Implications for insulin-like actions at the adipocyte. J Endocrinol 174:289-297.
36. Silha JV, Mishra S, Rosen CJ, Beamer WG, Turner RT, Powell DR, Murphy LJ. 2003. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res 18:1834-1841.
37. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS. 1988. Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 263:9402-9408.
38. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. 2008. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci USA 105:19378-19383.
39. Sul HS. 2009. Minireview: Pref-1: Role in adipogenesis and mesenchymal cell fate. Mol Endocrinol 23:1717-1725.
40. Terrien X, Bonvin E, Corroyer S, Tabary O, Clement A, Henrion Caude A. 2005. Intracellular colocalization and interaction of IGF-binding protein-2 with the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during growth inhibition. Biochem J 392:457-465. (Pubitemid 43022724)
41. van den Beld AW, Blum WF, Pols HA, Grobbee DE, Lamberts SW. 2003. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol 148:627-634.
42. Villafuerte BC, Fine JB, Bai Y, Zhao W, Fleming S, DiGirolamo M. 2000. Expressions of leptin and insulin-like growth factor-I are highly correlated and region-specific in adipose tissue of growing rats. Obes Res 8:646-655.
43. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SC, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK, Crossey PA. 2007. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56:285-294.
44. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329. (Pubitemid 29299660)
45. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. 2002. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771-781.
46. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. 2002. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012.
47. Zhang H, Noohr J, Jensen CH, Petersen RK, Bachmann E, Teisner B, Larsen LK, Mandrup S, Kristiansen K. 2003a. Insulin-like growth factor-1/insulin bypasses Pref-1/FA1-mediated inhibition of adipocyte differentiation. J Biol Chem 278:20906-20914.
48. Zhang M, Faugere MC, Malluche H, Rosen CJ, Chernausek SD, Clemens TL. 2003b. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res 18:836-843. (Pubitemid 37294966)
49. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674-2682.